In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

Antimicrobial Agents and Chemotherapy
Michael D HubandHelio S Sader

Abstract

Thein vitroantibacterial activities of ceftazidime-avibactam and comparator agents were evaluated using reference broth microdilution methods against 1,743Pseudomonas aeruginosaisolates collected in 2014 from 69 U.S. medical centers, representing each of the nine census regions. Ceftazidime-avibactam demonstrated potent activity againstP. aeruginosa, including many isolates not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam. In each of the nine census regions, ceftazidime-avibactam demonstrated the highest percentage of susceptible isolates.

References

Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Apr 28, 2010·Antimicrobial Agents and Chemotherapy·Laurent PoirelL Silvia Munoz-Price
Jul 3, 2010·Critical Care : the Official Journal of the Critical Care Forum·Karen Bush
Jun 15, 2011·Trends in Microbiology·Elena B M BreidensteinRobert E W Hancock
Dec 24, 2014·Antimicrobial Agents and Chemotherapy·Henry LiKaren Bush
Jul 2, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·C M GossnerUNKNOWN European Food and Waterborne Diseases Study Group

❮ Previous
Next ❯

Citations

Apr 22, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David van Duin, Robert A Bonomo
Oct 16, 2016·Current Infectious Disease Reports·Andre ArizpeSamuel L Aitken
Nov 8, 2017·Infection·Felipe Francisco TuonMarcelo R Formigoni-Pinto
Aug 18, 2017·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Michael J Satlin, Thomas J Walsh
Oct 10, 2018·Current Opinion in Infectious Diseases·Matteo BassettiBenoit Guery
Dec 15, 2019·European Journal of Clinical Pharmacology·Shampa DasJianguo Li
Aug 1, 2018·Antimicrobial Agents and Chemotherapy·Wright W NicholsShampa Das
Jun 8, 2018·Current Infectious Disease Reports·Lynn NguyenConan MacDougall
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei Doi
Jul 25, 2021·Paediatric Drugs·Anil R MaharajUNKNOWN Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
Oct 13, 2021·Current Opinion in Infectious Diseases·Matteo BassettiDaniele Roberto Giacobbe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.